Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650376 | 0.79 | HSPA5 (0.50) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| Hydrochloric Acid SCHEMBL6649318 | 0.77 | HSPA5 (0.48) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL6649041 | 0.75 | HSPA5 (0.49) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL12309156 | 0.71 | HSPA5 (0.68) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL34162 | 0.70 | HSPA5 (1.00) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL29351672 | 0.70 | HSPA5 (1.00) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL2230912 | 0.70 | HSPA5 (0.78) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL29558774 | 0.70 | HSPA5 (0.78) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL29415372 | 0.70 | HSPA5 (1.00) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL23389375 | 0.70 | HSPA5 (0.65) | HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260358-B2 | Process for oligomerization of olefins that uses a catalytic composition that comprises an organometallic complex that contains a phenoxy ligand that is functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9260358-B2 | Process for oligomerization of olefins that uses a catalytic composition that comprises an organometallic complex that contains a phenoxy ligand that is functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20110213190-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS A PHENOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP (FR) | 2011-09-01 | — | — | US | disclosed |
| US-20110213190-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS A PHENOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP (FR) | 2011-09-01 | — | — | US | disclosed |
| WO-2008142295-A1 | METHOD FOR OLIGOMERISING OLEFINS USING A CATALYTIC COMPOSITION COMPRISING AN ORGANOMETAL COMPLEX CONTAINING A PHENOXY LIGAND FUNCTIONALISED BY A HETEROATOM | IFP (FR) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213190-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS A PHENOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | HAO2, CPNE4, POF1B | HSPA5 2892/4885SMN1; SMN2 4735/4885CYP2C9 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.